Kidney disease and insulin resistance--clinical impact of thiazolidinedione compounds for kidney disease
Isshiki, K.; Haneda, M.; Koya, D.; Kikkawa, R.
Nihon Rinsho. Japanese Journal of Clinical Medicine 58(2): 440-445
2000
ISSN/ISBN: 0047-1852 PMID: 10707573 Document Number: 522487
The thiazolidinedione compounds are well known hypoglycemic agents via increasing insulin-sensitivity. Herein, we provide the possibility that thiazolidinedione compounds could be useful for renal dysfunction through mechanism dependent or independent of its insulin-sensitizing action. In type 2 diabetes, troglitazone could reduce urinary albumin-creatinine ratio compared to metformin. Furthermore, we have shown that troglitazone was able to prevent diabetic glomerular dysfunction through inhibition of diacylglycerol-protein kinase C-extracellular signal-regulated kinase pathway in type 1 diabetic rats. Thus, thiazolidinediones might be effective agents for treating insulin-resistant diabetes as well as diabetes-induced kidney disease.